← Leaderboards
Valerian Nakaar
Carogen Corporation
$5,207,630
Attributed
$5,207,630
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,943,639 · 3
CDC$263,991 · 1
By mechanism
R44$4,418,929 · 1
R43$788,701 · 3
Top collaborators
No co-investigators on record.
Research focus
Cd8-Positive T-LymphocytesMouse ModelImmunotherapyVectorVaccinesAntibodiesT Cell ResponseVirusHepatitis B VirusVesicleLiverLiver DiseasesToxicologyCirrhosisTherapeutic VaccinePrimary Carcinoma Of The Liver CellsBaseRegimenFeedbackHepatitis B Surface AntigensDesignHepatitis B Core AntigenAffectLegal Patent
Grant awards (8)
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV$1,140,300
R44 · FY2023 · DK · contact PI
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV$954,675
R44 · FY2022 · DK · contact PI
PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine$263,991
R43 · FY2022 · IP · contact PI
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV$939,695
R44 · FY2021 · DK · contact PI
DEVELOPING MULTI-ANTIGEN VACCINE FOR THE TREATMENT OF CHRONIC HBV$768,496
R44 · FY2020 · DK · contact PI
VLVs as platform for nucleic acid-based delivery:Combining therapeutic vaccine with shRNA-mediated PD-L1 blockade for the treatment of chronic hepatitis B virus$300,000
R43 · FY2020 · AI · contact PI
DEVELOPING MULTI-ANTIGEN VACCINE FOR THE TREATMENT OF CHRONIC HBV$615,763
R44 · FY2019 · DK · contact PI
Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV$224,710
R43 · FY2018 · DK · contact PI